• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Springworks Therapeutics Inc (NQ: SWTX )

    30.62 +0.49 (+1.63%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Springworks Therapeutics Inc

    < Previous 1 2 3 4 Next >
    La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday
    U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Analyst Ratings for SpringWorks Therapeutics
    Via Benzinga
    SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
    Via Benzinga
    SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Near the Top of Equities by Percentage Gain on 11/28
    Via Investor Brand Network
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    SpringWorks Catapults 24% On A 'Watershed Moment' In Cancer Treatment
    The company gained FDA approval for Ogsiveo, a treatment for desmoid tumors. 
    Via Investor's Business Daily
    Exposures Product Safety
    PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
    Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults... 
    Via Benzinga
    Exposures Product Safety
    Analyst Ratings for SpringWorks Therapeutics
    Via Benzinga
    Analyst Ratings for SpringWorks Therapeutics
    Via Benzinga
    The Latest Analyst Ratings for SpringWorks Therapeutics
    Via Benzinga
    FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas
    The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who  
    Via Benzinga
    Exposures Product Safety
    SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    HC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know
    Via Benzinga
    What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today?
    SpringWorks Therapeutics Inc (NASDAQ: SWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with... 
    Via Benzinga
    SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics: Q1 Earnings Insights
    Via Benzinga
    SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update
    In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQ: SWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which... 
    Via Benzinga
    Exposures Product Safety
    SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
    FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023 
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
    EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
    Via FinancialNewsMedia
    SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.